Immutep Limited

IMMP

$2.03

Name : Immutep Limited

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $297,976,544.00

EPSttm : -0.28

Immutep Limited

$2.03

2.40%

$0.05

Float Short %

2.92

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

-0.03

Price

2.09

Target Price

8.06

Analyst Recom

1.43

Performance Q

23.08

Relative Volume

4.36

Beta

1.89

Ticker: IMMP

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	IMMP	1.71	0.06	0.00	3355
2025-09-09	IMMP	1.62	0.06	0.00	3568
2025-09-10	IMMP	1.64	0.06	0.00	3682
2025-09-11	IMMP	1.65	0.05	0.00	3958
2025-09-12	IMMP	1.64	0.05	0.00	3957
2025-09-15	IMMP	1.7399	0.05	0.00	4079
2025-09-16	IMMP	1.68	0.05	0.00	4080
2025-09-17	IMMP	1.67	0.049116864263247	0	4336
2025-09-18	IMMP	1.695	0.05	0.00	4336
2025-09-19	IMMP	1.63	0.05	0.00	4336
2025-09-22	IMMP	1.7	0.05	0.00	4289
2025-09-23	IMMP	1.66	0.05	0.00	4294
2025-09-24	IMMP	1.7	0.05	0.00	4345
2025-09-25	IMMP	1.69	0.05	0.00	4347
2025-09-26	IMMP	1.72	0.05	0.00	4336
2025-09-29	IMMP	1.78	0.05	0.34	4338
2025-09-30	IMMP	1.79	0.05	0.11	4391
2025-10-01	IMMP	1.8	0.05	0.00	4457
2025-10-02	IMMP	1.88	0.05	0.43	4484
2025-10-03	IMMP	1.865	0.05	0.10	4508
2025-10-06	IMMP	1.955	0.05	0.06	4656
2025-10-07	IMMP	2.09	0.05	0.00	4668
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	IMMP	1.72	-	-	-0.24
2025-09-09	IMMP	1.61	-	-	-0.24
2025-09-10	IMMP	1.64	-	-	-0.24
2025-09-11	IMMP	1.66	-	-	-0.24
2025-09-12	IMMP	1.63	-	-	-0.24
2025-09-15	IMMP	1.73	-	-	-0.24
2025-09-16	IMMP	1.69	-	-	-0.24
2025-09-17	IMMP	1.67	-	-	-0.24
2025-09-18	IMMP	1.70	-	-	-0.24
2025-09-19	IMMP	1.62	-	-	-0.24
2025-09-22	IMMP	1.71	-	-	-0.24
2025-09-23	IMMP	1.66	-	-	-0.24
2025-09-24	IMMP	1.70	-	-	-0.24
2025-09-25	IMMP	1.68	-	-	-0.24
2025-09-26	IMMP	1.72	-	-	-0.24
2025-09-29	IMMP	1.78	-	-	-0.24
2025-09-30	IMMP	1.77	-	-	-0.24
2025-10-01	IMMP	1.80	-	-	-0.24
2025-10-02	IMMP	1.88	-	-	-0.24
2025-10-03	IMMP	1.87	-	-	-0.24
2025-10-06	IMMP	1.96	-	-	-0.24
2025-10-07	IMMP	2.09	-	-	-0.24
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	IMMP	0.00	35.96	2.91
2025-09-09	IMMP	0.00	35.96	2.91
2025-09-10	IMMP	0.00	35.96	2.91
2025-09-11	IMMP	0.00	35.96	2.95
2025-09-12	IMMP	0.00	35.96	2.95
2025-09-15	IMMP	0.00	-28.14	2.95
2025-09-16	IMMP	0.00	-28.14	2.95
2025-09-17	IMMP	0.00	-28.14	2.95
2025-09-18	IMMP	0.00	-28.14	2.95
2025-09-19	IMMP	0.00	-28.14	2.95
2025-09-22	IMMP	0.00	-26.14	2.95
2025-09-23	IMMP	0.00	-26.14	2.95
2025-09-24	IMMP	0.00	-26.14	2.95
2025-09-25	IMMP	0.00	-26.14	2.93
2025-09-26	IMMP	0.00	-26.14	2.93
2025-09-29	IMMP	0.00	-27.24	2.93
2025-09-30	IMMP	0.00	-27.24	2.93
2025-10-01	IMMP	0.00	-27.24	2.93
2025-10-02	IMMP	0.00	-27.24	2.93
2025-10-03	IMMP	0.00	-27.24	2.92
2025-10-06	IMMP	0.00	-16.11	2.92
2025-10-07	IMMP	0.00	-16.11	2.92
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-16.11

Beta

1.89

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

73.7

Max Drawdown 5-Year %

-75.2

Target Price

8.06

P/E

Forward P/E

PEG

P/S

P/B

3.23

P/Free Cash Flow

EPS

-0.27

Average EPS Est. Cur. Y

-0.24

EPS Next Y. (Est.)

-0.27

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

4.36

Return on Equity vs Sector %

-50.6

Return on Equity vs Industry %

-36.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Immutep Limited

Sector: Healthcare

Industry: Biotechnology

Employees:

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

stock quote shares IMMP – Immutep Limited ADR Stock Price stock today

news today IMMP – Immutep Limited ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch IMMP – Immutep Limited ADR yahoo finance google finance

stock history IMMP – Immutep Limited ADR invest stock market

stock prices IMMP premarket after hours

ticker IMMP fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IMMP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y